很高兴看到我们的 COMPANION-002 试验结果发表在 JCO，并在 #ESMO26 上展示！
一线治疗后，晚期胆道癌的治疗选择仍然有限，尤其是在没有可靶向突变的情况下。
Tovecimig + paclitaxel 对比 paclitaxel 单独治疗：
• 肿瘤缓解率（ORR）：18% 对比 5.3%
• 无进展生存期（中位 PFS）：4.7 对比 2.6 个月（HR 0.44）
很自豪能参与这项多中心试验！
219 浏览 · 0 赞 · 0 转发 · 0 回复
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org‼️ #ESMO26 simultaneous publication by Azad, et al. COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel Versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract Cancer Read full publication: https://bit.ly/4i2ZdwI在 X 查看被引用的帖子
来源：ilyas sahin, MD · x.com